

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

ANNOUNCEMENT
(1) PROPOSED CHANGE OF BUSINESS SCOPE;
AND
(2) PROPOSED AMENDMENT OF ARTICLES OF
ASSOCIATION

A meeting of the board of directors (the “**Board**”) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) was convened on August 26, 2021, at which, among others, the resolutions regarding (i) the change of business scope; and (ii) the amendment of the articles of association of the Company (the “**Articles of Association**”) were considered and approved.

The Board hereby announces that:

I. PROPOSED CHANGE OF BUSINESS SCOPE

To satisfy the business needs of the Company, the Board proposes to expand the business scope of the Company to include non-residential property leasing and residential property leasing, primarily for providing rest areas and accommodation for its employees.

The proposed change of business scope is conditional upon the following conditions being satisfied:

- (i) passing of special resolution by the shareholders of the Company (the “**Shareholders**”) at the 2021 first extraordinary general meeting of the Company (the “**EGM**”) to approve the change of business scope; and
- (ii) obtaining all the necessary approvals from the Market Supervision and Regulation Bureau of Shenzhen Municipality for the change of business scope.

The application for and filing of change and registration with the Market Supervision and Regulation Bureau of Shenzhen Municipality will be made by the Company after the passing of the relevant special resolution at the EGM. The proposed change of business scope will take effect from the date on which the business licence in relation to the amended business scope is issued by the Market Supervision and Regulation Bureau of Shenzhen Municipality.

II. PROPOSED AMENDMENT OF THE ARTICLES OF ASSOCIATION

In view of the proposed change of the Company's business scope, the Board proposes to amend the Articles of Association as follows:

Existing Terms of the Articles of Association	Proposed Amendment to the Articles of Association
<p>Article 14 The legally registered business scope of the Company is: development and production of APIs (heparin sodium and enoxaparin sodium), import and export of goods and technologies (excluding goods for distribution or specially operated, controlled or sold by the state).</p> <p>The Company may change its business scope according to laws, based on demands in domestic and international markets and its own development capability and business needs.</p>	<p>Article 14 The legally registered business scope of the Company is: development and production of APIs (heparin sodium and enoxaparin sodium), import and export of goods and technologies (excluding goods for distribution or specially operated, controlled or sold by the state), <u>non-residential property leasing and residential property leasing</u>.</p> <p>The Company may change its business scope according to laws, based on demands in domestic and international markets and its own development capability and business needs.</p>

The business scope as referred to above shall be subject to the approval of registration by the Market Supervision and Regulation Bureau of Shenzhen Municipality.

Save for the aforementioned article, the contents of other articles in the Articles of Association remain unchanged.

The Articles of Association are prepared in Chinese. In the event of any discrepancy between the English translation and the Chinese version, the Chinese version shall prevail.

The proposed amendment to the Articles of Association is subject to the approval of the Shareholders at the EGM by way of a special resolution.

III. CIRCULAR

A circular containing, among other things, further details regarding (1) the change of the Company's business scope; (2) the amendment of the Articles of Association; and (3) a notice of the EGM will be dispatched to the Shareholders in due course.

By Order of the Board of Directors
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
August 26, 2021

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Bin; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.